Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 14/20 | 0.48 |
| ▸ | MMP1 | P03956 | 10/20 | 0.48 |
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | FCER2 | P06734 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764984 | 1.00 | MMP3 (0.48) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL6413230 | 0.88 | MMP3 (0.45) | MMP3MMP1MMP2ADAM17TNF | |
| SCHEMBL8665728 | 0.87 | MMP3 (0.44) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8667836 | 0.87 | FCER2 (0.48) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8664100 | 0.87 | MMP2 (0.49) | MMP3MMP1MMP2ADAM17TNF | |
| SCHEMBL6418840 | 0.85 | FCER2 (0.40) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL6412000 | 0.85 | FCER2 (0.44) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8663575 | 0.80 | MMP3 (0.46) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL8668754 | 0.78 | MMP3 (0.58) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL8665565 | 0.77 | MMP3 (0.56) | MMP3MMP1MMP2MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0712390-B1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-09 | — | — | EP | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-0712390-B1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-09 | — | — | EP | disclosed |
| EP-0712390-A1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004033-A1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP2 19/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP2 19/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MMP1 20/4885MMP2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.